Incyte Corporation reported total revenue of $1.56 billion for the third quarter of 2026, a 14% increase compared to the same period in 2025. Total net sales for the quarter were $1.32 billion, also up 14% year-over-year. The company reported that Jakafi and Jakafi XR net sales reached $827 million, representing a 4% increase from the prior year.
Core business performance showed significant growth, with Opzelura net sales increasing 36% to $255 million and Hematology and Oncology net sales rising 38% to $235 million. Cost of sales was reported at 8% of total net sales. Research and development expenses increased significantly due to a $1.23 billion one-time intellectual property and research and development expense related to the acquisition of Vega Therapeutics.
Incyte raised its full-year 2026 net sales guidance for Opzelura to $1.1 billion to $1.12 billion, for Hematology and Oncology to $890 million to $910 million, and for total net sales to $5.21 billion to $5.30 billion. The company also provided updates on its pipeline, including Phase 3 data expected by year-end for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa. Additionally, Incyte announced the completion of its acquisition of Vega Therapeutics for $1.25 billion.
